WAILEA, Hawaii — In this Healio video perspective, Mark L. Baum, chairman and CEO at Harrow, discusses the launch of Vevye ophthalmic solution for the treatment of dry eye disease, here at Hawaiian Eye 2024.
“We are talking about better bioavailabilty, onset of action that is fast for your patient, durability of effect — we have data going out to 56 weeks with continued improvement in signs and symptoms — and finally incredible tolerability,” Baum told Healio.
Vevye is a preservative-free, twice-daily 0.1% cyclosporine ophthalmic solution indicated for treatment of